Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals

Video

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed how the results of a longer term study differ for individuals who were younger as opposed to those who are older.

Related Videos
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Ozempic, obesity, drug shortage, media portrayal | Image Credit: zimmytws - stock.adobe.com
Doctor using a stethoscope checking patient with examining, presenting results symptom and recommend treatment method, Healthcare and medical concept - Image credit: Ngampol | stock.adobe.com
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig - stock.adobe.com
Sleep Apenea C-PAP Machine | Image Credit: sbw19 - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
© 2024 MJH Life Sciences

All rights reserved.